NYSE:MED Medifast (MED) Stock Price, News & Analysis $18.99 +0.17 (+0.90%) (As of 09/19/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Medifast alerts: Email Address About Medifast Stock (NYSE:MED) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Medifast alerts:Sign Up Key Stats Today's Range$18.85▼$19.2250-Day Range$17.91▼$21.9652-Week Range$17.73▼$83.60Volume117,004 shsAverage Volume430,044 shsMarket Capitalization$207.75 millionP/E Ratio3.06Dividend YieldN/APrice Target$49.75Consensus RatingReduce Company OverviewMedifast, Inc., through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names. The company markets its products through point-of-sale transactions, as well as through ecommerce platform. Medifast, Inc. was founded in 1980 and is headquartered in Baltimore, Maryland.Read More… We recommended Nvidia in 2016, now we’re recommending this… (Ad)The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. Medifast Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 68th PercentileMedifast scored higher than 68% of companies evaluated by MarketBeat, and ranked 72nd out of 149 stocks in the consumer staples sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.8 / 5Analyst RatingReduce Consensus RatingMedifast has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageMedifast has only been the subject of 1 research reports in the past 90 days.Read more about Medifast's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth-31.39% Earnings GrowthEarnings for Medifast are expected to decrease by -31.39% in the coming year, from $1.37 to $0.94 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Medifast is 3.06, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 131.01.Price to Earnings Ratio vs. SectorThe P/E ratio of Medifast is 3.06, which means that it is trading at a less expensive P/E ratio than the Consumer Staples sector average P/E ratio of about 22.52.Price to Book Value per Share RatioMedifast has a P/B Ratio of 1.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Medifast's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.51% of the float of Medifast has been sold short.Short Interest Ratio / Days to CoverMedifast has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Medifast has recently decreased by 4.61%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMedifast does not currently pay a dividend.Dividend GrowthMedifast does not have a long track record of dividend growth. Sustainability and ESG2.0 / 5Environmental Score-4.00 Percentage of Shares Shorted19.51% of the float of Medifast has been sold short.Short Interest Ratio / Days to CoverMedifast has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Medifast has recently decreased by 4.61%, indicating that investor sentiment is improving. News and Social Media1.3 / 5News Sentiment0.31 News SentimentMedifast has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Consumer Staples companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Medifast this week, compared to 3 articles on an average week.Search InterestOnly 5 people have searched for MED on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Medifast to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Medifast insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.50% of the stock of Medifast is held by insiders.Percentage Held by Institutions95.51% of the stock of Medifast is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Medifast's insider trading history. Receive MED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medifast and its competitors with MarketBeat's FREE daily newsletter. Email Address MED Stock News HeadlinesMedifast (MED): A Bull Case TheorySeptember 11, 2024 | msn.comPersonal Care Stocks Q2 Results: Benchmarking Medifast (NYSE:MED)September 11, 2024 | finance.yahoo.comWhy You Should NOT Trade This MarketYou'll be interested in our 5-Day Options Trading Challenge, starting September 23. So, what makes this different from every other options research you may have seen? Well, for starters... most of them want you to first BUY their service... which is usually thousands of dollars...September 19, 2024 | InvestorPlace (Ad)The Schall Law Firm Is Looking Into Medifast Inc For Possible Securities Law Violations And Investors With Losses Should Reach OutSeptember 11, 2024 | stockhouse.comIs Now An Opportune Moment To Examine Medifast, Inc. (NYSE:MED)?September 8, 2024 | finance.yahoo.comSpotting Winners: Edgewell Personal Care (NYSE:EPC) And Personal Care Stocks In Q2September 4, 2024 | theglobeandmail.comMedifast: Reorganization, GLP-1 Medication, And FCF Imply UndervaluationSeptember 4, 2024 | seekingalpha.comMedifast Business Continues To Shrink, Stock Still RiskyAugust 27, 2024 | seekingalpha.comSee More Headlines MED Stock Analysis - Frequently Asked Questions How have MED shares performed this year? Medifast's stock was trading at $67.22 at the start of the year. Since then, MED shares have decreased by 71.7% and is now trading at $18.99. View the best growth stocks for 2024 here. How were Medifast's earnings last quarter? Medifast, Inc. (NYSE:MED) released its quarterly earnings data on Monday, August, 5th. The specialty retailer reported $0.92 EPS for the quarter, beating the consensus estimate of $0.36 by $0.56. The specialty retailer had revenue of $168.56 million for the quarter, compared to analysts' expectations of $160.44 million. Medifast had a net margin of 3.81% and a trailing twelve-month return on equity of 25.77%. Who are Medifast's major shareholders? Top institutional investors of Medifast include Renaissance Technologies LLC (8.76%), Millennium Management LLC (4.29%), AQR Capital Management LLC (3.57%) and Acadian Asset Management LLC (3.09%). Insiders that own company stock include Daniel R Chard, Scott Schlackman, Andrea B Thomas, Jeffrey J Brown and Constance J Hallquist. View institutional ownership trends. How do I buy shares of Medifast? Shares of MED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Medifast own? Based on aggregate information from My MarketBeat watchlists, some other companies that Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Home Depot (HD), Boeing (BA), Johnson & Johnson (JNJ) and Intel (INTC). Company Calendar Last Earnings8/05/2024Today9/19/2024Next Earnings (Estimated)11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorConsumer Staples Industry Miscellaneous food preparations & kindred products Sub-IndustryPersonal Products Current SymbolNYSE:MED CUSIP58470H10 CIK910329 Webwww.medifast1.com Phone(410) 581-8042Fax410-581-8070Employees870Year FoundedN/APrice Target and Rating Average Stock Price Target$49.75 High Stock Price Target$82.00 Low Stock Price Target$17.50 Potential Upside/Downside+162.0%Consensus RatingReduce Rating Score (0-4)1.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$6.20 Trailing P/E Ratio3.06 Forward P/E Ratio13.86 P/E GrowthN/ANet Income$99.42 million Net Margins3.81% Pretax Margin4.84% Return on Equity25.77% Return on Assets17.04% Debt Debt-to-Equity RatioN/A Current Ratio2.98 Quick Ratio2.46 Sales & Book Value Annual Sales$1.07 billion Price / Sales0.19 Cash Flow$11.04 per share Price / Cash Flow1.72 Book Value$18.50 per share Price / Book1.03Miscellaneous Outstanding Shares10,940,000Free Float10,664,000Market Cap$207.75 million OptionableOptionable Beta1.13 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NYSE:MED) was last updated on 9/19/2024 by MarketBeat.com Staff From Our PartnersUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adopti...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medifast, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medifast With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.